News

Research Fellow, Dr Alene Yong from the Centre of Medicine Use and Safety presented an overview on the development of an Australian Guideline on the appropriate use of MDMA-assisted psychotherapy for post-traumatic stress disorder.

Congratulations to Prof. Chris Langmead and Dr. Greg Stewart who were the winners of the Monash University Vice-Chancellor’s Excellence Award for their work in Translation and Commercialisation of Neuromedicines.

Congratulations to Dr David Bibby, CEO and Co-Founder of Pacalis Therapeutics Pty Ltd who was announced as the joint winner of the Early-Stage Innovation Forum at the 2024 AusBiotech annual meeting.

Director of the NDC, Professor Chris Langmead moderated a session entitled ‘Psychedelics in psychiatric disorders: Where are we now and where to next?’ at the 2024 AusBiotech annual meeting.

Phrenix Therapeutics CEO and Co-Founder, Chris Langmead along with team members Greg Stewart and Aimee Freeburn were thrilled to participate in the recent Monash Generator Showcase.

Researchers from Monash University’s Faculty of Pharmacy and Pharmaceutical Sciences have made significant contributions to pave the way for the development of a new class of medicine for schizophrenia in more than 30 years.

The US FDA has approved a new medication for schizophrenia. Cobenfy is a combination of two medicines – xanomeline  and trospium, that improves the negative and cognitive symptoms of schizophrenia while minimising side effects.

On Wednesday 25 September, eating disorder experts and advocates from around the world gathered in Melbourne for the launch of the CoRe-ED, a first-of-its-kind international initiative dedicated to advancing treatments for eating disorders.

Our NDC Director, Professor Chris Langmead joined a fabulous group of students at the Students of Brain Research (SOBR) 2024 networking dinner.